Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-08-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2010-11-320093PMID 21613261PMCID PMC3156041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

  2010cited by this paper
• Epigenetic changes in the myelodysplastic syndrome.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

  2010cited by this paper
• Count Recovery in AML Patients Achieving a Complete Response.

  2009cited by this paper
• Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method

  2007cited by this paper
• Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

  2007cited by this paper
• Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines

  2007cited by this paper
• Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

  2006cited by this paper
• DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

  2006cited by this paper
• Decitabine in acute myeloid leukemia.

  2005cited by this paper
• Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

  2005cited by this paper
• Analysis of repetitive element DNA methylation by MethyLight

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Pharmacodynamic and DNA methylation studies of high-dose 1-β-d-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia

  2004cited by this paper
• Hematopoietic Recovery Following Induction Therapy of Acute Leukemias: Prognostic Implications and a New Look at the Definition of Remission

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission

  2002cited by this paper
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

  2002cited by this paper
• Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix

  2002cited by this paper
• Methylation profiling in acute myeloid leukemia.

  2001cited by this paper
• Sensitization by 5‐aza‐2′‐deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all‐trans retinoic acid and 1α,25‐dihydroxyvitamin D3

  2001cited by this paper
• Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

  2000cited by this paper
• Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

  2000cited by this paper
• Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.

  2000cited by this paper
• A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer

  2000cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

  2000cited by this paper
• Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia.

  1999cited by this paper
• Alterations in DNA methylation: a fundamental aspect of neoplasia.

  1998cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• The role of DNA methylation in cancer genetic and epigenetics.

  1996cited by this paper
• THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS

  1996cited by this paper
• Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.

  1991cited by this paper
• Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.

  1990cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs.

  1983cited by this paper
• Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.

  1983cited by this paper
• Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.

  1981cited by this paper
• Cellular differentiation, cytidine analogs and DNA methylation.

  1980cited by this paper
• Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.

  1978cited by this paper

• DIA Regimen Versus IA Regimen for Induction Therapy in Younger Adults With Acute Myeloid Leukemia: A Multicenter Open‐Label Randomized Controlled Trial

  2025cites this paper
• Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.

  2025cites this paper
• Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients

  2024cites this paper
• An integrated framework for the study of exercise across the postdiagnosis cancer continuum

  2024cites this paper
• Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

  2023cites this paper
• Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy

  2023cites this paper
• Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

  2023cites this paper
• Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

  2022cites this paper
• Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies

  2021cites this paper
• Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients

  2021cites this paper
• Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

  2021cites this paper
• Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

  2021cites this paper
• Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia

  2021cites this paper
• A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes

  2021cites this paper
• A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia

  2021cites this paper
• Azacitidine plus low-dose CLAG regimen for relapsed/refractory acute myeloid leukemia: A case report

  2021cites this paper
• The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning

  2021cites this paper
• Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.

  2020cites this paper
• DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia

  2020cites this paper
• Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

  2020cites this paper
• Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2

  2020cites this paper
• Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis

  2020cites this paper
• Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

  2020cites this paper
• Emerging treatment options for patients with high-risk myelodysplastic syndrome

  2020cites this paper
• Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

  2020influential citation
• A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

  2020cites this paper
• Decitabine as a treatment choice for de novo acute basophilic leukemia: transient response-a case report

  2020cites this paper
• Fezf2 transient expression via modRNA with concurrent SIRT1 inhibition enhances differentiation of cortical subcerebral / corticospinal neuron identity from mES cells

  2020cites this paper
• Correction to: Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report

  2019cites this paper
• Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

  2019cites this paper
• Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study

  2019cites this paper
• Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors

  2019cites this paper
• Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

  2019cites this paper
• Pharmacoepigenetics of Acute Myeloid Leukemia

  2019cites this paper
• AGR2 is controlled by DNMT3a-centered signaling module and mediates tumor resistance to 5-Aza in colorectal cancer.

  2019cites this paper
• A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features

  2019cites this paper
• Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report

  2019cites this paper
• Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy

  2019cites this paper
• Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

  2018cites this paper
• Epigenetic changes and their implications in autoimmune hepatitis

  2018cites this paper
• Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic.

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia

  2018cites this paper
• Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management

  2018cites this paper
• NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer

  2018cites this paper
• Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

  2018cites this paper
• How I treat older patients with acute myeloid leukemia

  2018cites this paper
• Untangling the Role of Polycomb Complexes in Chemotherapy Resistance.

  2018cites this paper
• Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis

  2017cites this paper
• Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

  2017cites this paper
• A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML

  2017cites this paper
• Decitabine prior to low-dose cytarabinebased cytarabinebased cytarabinebased chemotherapy combined with HLAmismatched HLAmismatched HLAmismatched stem cell microtransplantation microtransplantation microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukaemi

  2017cites this paper
• Combination Epigenetic Therapy

  2017cites this paper
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study

  2017influential citation
• A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia.

  2017cites this paper
• Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

  2017cites this paper
• A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485

  2017cites this paper
• Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs

  2016cites this paper
• Epigenetics in Brain Tumors: HDACs Take Center Stage

  2016cites this paper
• Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer

  2016cites this paper
• Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

  2016cites this paper
• Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

  2016influential citation
• What is memory? The present state of the engram

  2016cites this paper
• Epigenetics: A primer for clinicians.

  2016cites this paper
• Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

  2016influential citation
• A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High‐Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia

  2016cites this paper
• Hypomethylation of TET 2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia

  2016cites this paper
• Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

  2016cites this paper
• Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia

  2015cites this paper
• Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents

  2015cites this paper
• Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS.

  2015cites this paper
• D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation

  2015cites this paper
• Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

  2015cites this paper
• The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients

  2015cites this paper
• Epigenetic signaling in schizophrenia.

  2015cites this paper
• Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?

  2015cites this paper
• Methylation in aml: Clinical applications

  2015cites this paper
• Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials

  2015cites this paper
• The Epigenetic Regulation of KCNA5 in Pediatric Solid Tumors and its Role in Cancer Biology.

  2015cites this paper
• DECITABINE FOR MYELODYSPLASTIC SYNDROME AND ELDERLY ACUTE MYELOID LEUKEMIA -A TERTIARY CENTRE DATA FROM INDIA

  2014cites this paper
• Concise Review: Leukemia Stem Cells in Personalized Medicine

  2014cites this paper
• Epigenetic targeting and personalized approaches for AML.

  2014cites this paper
• Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?

  2014cites this paper
• overexpression in acute promyelocytic leukemia Loss of imprinting at the 14 q 32 domain is associated with microRNA

  2014cites this paper
• Development and classes of epigenetic drugs for cancer.

  2014cites this paper
• Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target

  2014cites this paper
• Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia

  2014influential citation
• The characterisation of telomere dynamics in Myelodysplastic syndromes

  2014cites this paper
• Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients

  2014cites this paper
• Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia.

  2014cites this paper
• Cancer Biology and Signal Transduction The Role of Gene Body Cytosine Modi fi cations in MGMT Expression and Sensitivity to Temozolomide

  2014cites this paper
• University of Birmingham Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia

  2014influential citation
• Neue Entwicklungen in der Therapie maligner hämatologischer Erkrankungen

  2014cites this paper
• Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia

  2014cites this paper
• The potential of HDAC inhibitors as cognitive enhancers.

  2013cites this paper
• Novel treatment options for acute myelocytic leukemia

  2013cites this paper
• locus and accelerates K-RAS driven myeloproliferative disorder in mice Hoxa9 The human GFI136N variant induces epigenetic changes at the

  2013cites this paper
• Decitabine for the treatment of acute myeloid leukemia

  2013cites this paper